Ginkgo Bioworks Holdings, Inc. provided revenue guidance for the year 2024. The company is expecting total revenue of $215 million - $235 million in 2024. The company expects Cell Engineering services revenue of $165 million -185 million in 2024 driven by expected growth in biopharma and government programs. This guidance excludes the impact of any potential downstream value share revenue.

The company expects Biosecurity revenue in 2024 of at least $50 million, representing approximate current contracted backlog, with potential upside from additional opportunities in the pipeline.